Autosomal Recessive Spastic Paraplegia Type 60 (SPG60)

Autosomal Recessive Spastic Paraplegia type 60 (SPG60) is a very rare genetic nerve disorder. It mainly affects the long nerve tracts that run from the brain down the spinal cord to the legs (the corticospinal tracts). Because these long nerves slowly stop working, the main signs are stiff, tight leg muscles (spasticity), trouble walking, and weakness in the lower limbs. In many reported patients, symptoms begin in infancy or early childhood and slowly get worse over time. Some people also have extra problems such as vibration-sense loss at the ankles, nystagmus (fast, shaky eye movements), sensory changes, a motor axonal neuropathy (a problem with the “motor” cables in the peripheral nerves), and mild intellectual disability. rarediseases.info.nih.gov+2Orpha+2

SPG60 is a rare, inherited nerve condition that usually begins in infancy or early childhood. It mainly stiffens and weakens the leg muscles, making walking hard. Some people also have eye movement problems (nystagmus), mild learning problems, and nerve damage to the legs. It is caused by harmful changes in the WDR48 gene (also called UAF1), which helps proteins involved in cell “clean-up” and DNA repair; when it does not work well, long nerve fibers in the spinal cord are especially vulnerable, so leg control suffers. Care is team-based and symptomatic. PMC+3rarediseases.info.nih.gov+3GeneCards+3

Scientifically, SPG60 belongs to the big family of disorders called hereditary spastic paraplegias (HSP)—conditions where the core feature is progressive walking difficulty from lower-limb spasticity. HSPs are classified as “pure” when problems are limited to the legs, and “complex” when there are extra features like neuropathy, ataxia, seizures, retinal or optic nerve involvement, or cognitive change. SPG60 is usually described as a complex HSP. Medscape+1

Other names

• SPG60

• Autosomal recessive spastic paraplegia type 60

• In coding systems you may also see Orphanet ORPHA:401800 and MONDO:0018417. rarediseases.info.nih.gov+2Orpha+2

SPG60 is caused by harmful changes (pathogenic variants) in a gene called WDR48, also known as UAF1. This gene helps control how cells recycle and clear proteins (through the ubiquitin system), and it is linked to endosomal trafficking and autophagy—the cell’s “sorting and cleanup” systems. When both copies of WDR48 in a person are altered (one from each parent), long spinal cord neurons are especially vulnerable, and the legs become weak and spastic over time. Evidence linking WDR48 to SPG60 comes from genetic databases and phenotype maps connecting this gene to the SPG60 label. Ensembl+2Promega+2

Inheritance is autosomal recessive. That means each parent is usually a healthy carrier with one changed copy of the gene. A child must inherit the changed gene from both parents to have SPG60. rarediseases.info.nih.gov

Note: HSPs overall are genetically diverse. Many genes can cause different HSP subtypes, and HSPs share many signs and exam findings. This is why gene testing is essential to pin down the exact type. JAMA Network+1

Types

Doctors often describe HSP subtypes as pure or complex.

• Pure HSP: problems mainly in the legs—spasticity, weakness, tight Achilles, urinary urgency; normal exam elsewhere.

• Complex HSP: leg problems plus extra features (for example, neuropathy, ataxia, seizures, eye movement problems, retinal or optic nerve disease, skin changes, or cognitive symptoms).

SPG60 is typically complex because reported patients often show spasticity plus sensory loss, nystagmus, motor axonal neuropathy, and sometimes mild intellectual disability. Medscape+1

---

Causes

The root cause is having two pathogenic variants in WDR48. Below are 20 focused “causes” and contributors expressed in simple language—some are direct molecular causes, others are contributors that increase the chance of disease in families or worsen the course. (For monogenic diseases like SPG60, many of these expand on how the defect harms cells or why it appears in some families.)

1. Biallelic WDR48 mutations – Two harmful changes, one on each copy of the gene, disrupt normal protein-recycling pathways in neurons. Ensembl+1

2. Loss-of-function variants – Truncating or splice-site changes can prevent the WDR48 protein from working. Ensembl

3. Missense variants with functional impact – A single “letter swap” in DNA can change the protein’s shape and reduce its activity. Ensembl

4. Disrupted deubiquitination complexes – WDR48 partners with deubiquitinases; when WDR48 is faulty, protein cleanup stalls and neurons accumulate damaged proteins. Ensembl

5. Endosomal trafficking defects – Traffic of cargo inside cells is mis-routed, stressing long corticospinal neurons. Ensembl

6. Autophagy impairment – The “self-eating” cleanup process is blunted; waste builds up; axons degenerate. Ensembl

7. Length-dependent axon vulnerability – Very long axons to the legs need perfect transport; small defects cause big problems. (General HSP mechanism.) American Academy of Neurology

8. Carrier-carrier marriages (consanguinity) – When relatives have children, both may carry the same rare variant, raising the chance of an affected child. (Autosomal-recessive principle.) rarediseases.info.nih.gov

9. Population founder variants – In small or isolated populations, a rare harmful change may be more common, increasing case clusters. (General HSP genetics.) ScienceDirect

10. Modifier genes – Other gene changes can worsen or shape symptoms, as seen in HSP more broadly. PubMed

11. Mitochondrial stress secondary to protein-homeostasis defects – Neurons burn energy constantly; waste buildup indirectly strains mitochondria. (Inferred from HSP pathobiology literature.)

12. Axonal transport abnormalities – Traffic of nutrients and signals along axons is inefficient; legs suffer first. (General HSP mechanism.) JAMA Network

13. Synaptic maintenance problems – Distal nerve endings become unhealthy when cellular recycling falters. (General HSP concept.) American Academy of Neurology

14. Developmental wiring vulnerability – In infancy, motor pathways are still maturing; early defects express as delayed motor milestones. (Supported by infant onset in SPG60.) rarediseases.info.nih.gov

15. Peripheral motor axon involvement – Not only central tracts but also peripheral motor axons may degenerate (motor axonal neuropathy). rarediseases.info.nih.gov

16. Sensory pathway involvement – Loss of vibration sense reflects dorsal-column or peripheral sensory-axon stress. rarediseases.info.nih.gov

17. Eye movement network involvement – Nystagmus suggests brainstem/cerebellar circuit sensitivity. rarediseases.info.nih.gov

18. Cognitive circuit susceptibility – Mild intellectual disability shows broader neural network effects in complex HSP. rarediseases.info.nih.gov

19. Natural aging – With time, stressed neurons cope less well, so symptoms become more obvious. (General HSP course.) PMC

20. Delayed diagnosis and missed therapy – Without early rehab and supportive care, stiffness and contractures progress faster. (HSP management principle.) Medscape

---

Symptoms

1. Stiff, tight leg muscles (spasticity) – The legs feel rigid; they resist movement and spring back; this makes walking hard. rarediseases.info.nih.gov

2. Leg weakness – The legs tire easily and feel heavy; getting up from the floor or climbing stairs is slow. (HSP core.) PMC

3. Abnormal gait / spastic gait – Steps are short and scissoring; knees may cross; feet may point down; balance is shaky. rarediseases.info.nih.gov

4. Tip-toe or toe-walking – Tight calves and ankle spasticity pull the heels up while walking. (Common in early-onset HSP.) Orpha

5. Frequent falls or tripping – Stiffness and poor foot clearance raise fall risk. (HSP general.) Medscape

6. Loss of vibration sense at the ankles – A tuning fork at the ankle feels faint or not at all; this is a typical SPG60 clue. rarediseases.info.nih.gov

7. Sensory changes in the feet – Numbness or tingling in toes or soles may appear. rarediseases.info.nih.gov

8. Motor axonal neuropathy signs – Distal muscle wasting, reduced ankle reflexes, or foot drop can show peripheral motor-nerve involvement. rarediseases.info.nih.gov

9. Nystagmus – Eyes make quick, jerky movements you can’t control; reading and tracking are harder. rarediseases.info.nih.gov

10. Mild intellectual disability or learning difficulty – Thinking and learning can be a little slower than peers. rarediseases.info.nih.gov

11. Urinary urgency – A strong, sudden need to urinate is common across HSP types. PMC

12. Muscle cramps – Tight, painful spasms in legs, especially after walking or at night. (HSP general.) Medscape

13. Fatigability – Tasks that involve standing or walking for long periods become exhausting. (HSP general.) PMC

14. Balance problems – Spasticity and sensory loss make balance and quick turns difficult. (HSP general.) Medscape

15. Contractures in ankles/knees over time – Untreated stiffness shortens tendons, fixing joints in a limited position. (HSP general.) Medscape

---

Diagnostic tests

A) Physical examination (bedside assessment)

1. Neurologic exam for spasticity and weakness – The doctor checks tone (how tight muscles feel), reflexes (often brisk at knees/ankles), and strength. Brisk reflexes and “clonus” point to corticospinal tract disease. PMC

2. Gait analysis – Watching how you walk shows scissoring, toe-walking, or stiff-leg pattern typical of spastic gait; this helps separate HSP from muscle or joint disease. Medscape

3. Sensory testing (vibration and position sense) – A tuning fork at the ankles and big toes checks vibration sense. In SPG60, vibration sense may be reduced. rarediseases.info.nih.gov

4. Cranial-nerve and eye-movement exam – The doctor looks for nystagmus, which supports a “complex” HSP picture like SPG60. rarediseases.info.nih.gov

5. Bladder screen – Simple questions about urinary urgency/frequency help detect common HSP autonomic symptoms. PMC

B) Manual / bedside functional tests

6. Timed Up-and-Go (TUG) – Measures how long it takes to stand, walk 3 meters, turn, and sit. Longer times indicate mobility limits from spasticity and weakness. (HSP functional tracking.) American Academy of Neurology

7. 10-Meter Walk Test – Counts speed and number of steps; spastic scissoring and toe-drag slow the pace; good for follow-up. (HSP functional tracking.) American Academy of Neurology

8. Modified Ashworth Scale for spasticity – The examiner moves the leg and rates how much resistance there is. Higher scores mean tighter muscles. (Widely used in spasticity care.) Medscape

9. Range-of-motion (ROM) testing – Manual goniometer checks ankle, knee, and hip motion; early detection of contractures guides therapy. Medscape

10. Foot examination for deformity – Looks for pes cavus or hammertoes from chronic imbalance; supports neuropathy involvement. (HSP + neuropathy overlap.) Medscape

C) Laboratory and pathological tests

11. Targeted or panel-based genetic testing – The key test. Next-generation sequencing panels for HSP or whole-exome/genome sequencing identify WDR48 variants to confirm SPG60. Family testing can show recessive inheritance. panelapp.genomicsengland.co.uk+1

12. Copy-number analysis – Detects missing or extra chunks in the WDR48 gene that standard sequencing might miss. (General genetic practice in HSP.) Orpha

13. Basic labs to rule out mimics – Vitamin B12, copper, thyroid levels, inflammatory markers, and infection screens exclude treatable causes of spastic paraparesis if genetic results are pending or unclear. (HSP differential approach.) Medscape

14. Metabolic work-up when indicated – If there are red flags (rapid course, multi-system disease), additional metabolic tests help exclude other neuro-metabolic disorders. (HSP differential.) Medscape

D) Electrodiagnostic tests

15. Nerve conduction studies (NCS) – Check speed and strength of electrical signals in peripheral nerves. In SPG60, studies may reveal motor axonal neuropathy consistent with the “complex” profile. rarediseases.info.nih.gov

16. Electromyography (EMG) – Needle test of muscles to confirm denervation or chronic axon loss when neuropathy is suspected. Helps separate central spasticity from peripheral motor nerve damage. (HSP work-up.) Medscape

17. Evoked potentials (e.g., somatosensory) – Measure conduction along sensory pathways in the spinal cord; delayed signals support dorsal-column involvement when vibration sense is reduced. (HSP physiology.) PMC

E) Imaging tests

18. Brain MRI – Often normal in pure HSP, but in complex types can show thin corpus callosum, white-matter changes, or other clues; helps rule out mimic disorders. (General HSP imaging.) PMC

19. Spinal MRI – Excludes structural causes (tumor, tethered cord) and assesses cord signal. In HSP, MRI may be unremarkable or show subtle atrophy. (General HSP imaging.) PMC

20. Ophthalmologic imaging/assessment – Eye exam and, when needed, ocular imaging are used if nystagmus or visual complaints are present, supporting the “complex” designation. (SPG60 phenotype.) rarediseases.info.nih.gov

Non-pharmacological treatments

1) Individualized physiotherapy (stretching + strengthening).
Goal: keep joints flexible, reduce stiffness, and maintain walking ability. Mechanism: daily hamstring/calf/hip flexor stretches lessen muscle over-activity and protect against contractures; progressive, low-load strengthening counters disuse weakness; task-specific gait drills reinforce more normal movement patterns. Evidence from HSP care reviews supports regular, structured PT as first-line. PMC+2Medscape+2

2) Gait training and balance therapy.
Goal: safer, more efficient walking. Mechanism: treadmill with body-weight support, over-ground practice, obstacle work, and cueing improve step length, cadence, and symmetry by repeatedly activating central gait circuits while keeping spasticity in check. Outcome measures (eg, 10-meter walk, Timed Up-and-Go) guide progress. PMC+1

3) Orthoses (AFOs, night splints).
Goal: prevent toe drag and ankle collapse; protect range. Mechanism: ankle-foot orthoses hold the ankle near neutral during swing/stance, reducing tripping and lowering calf spasticity triggers; resting splints keep muscles elongated overnight to resist contracture. PM&R KnowledgeNow+1

4) Spasticity-focused positioning & serial casting.
Goal: lengthen tight muscles safely. Mechanism: prolonged low-load stretch through casting or adjustable splints reduces reflex hyper-excitability and adds sarcomeres over time, improving dorsiflexion and knee extension without drugs. PM&R KnowledgeNow

5) Occupational therapy (ADL & equipment).
Goal: make dressing, bathing, and home/school tasks easier. Mechanism: task modification, energy conservation, seating/desk optimization, grab bars, and bathroom/bedroom layout changes cut fall risk and extend independence. PM&R KnowledgeNow

6) Assistive mobility devices.
Goal: safe mobility across distances. Mechanism: canes, forearm crutches, walkers, or lightweight wheelchairs reduce fall risk and fatigue by sharing load and providing stability; timely introduction prevents overexertion and injuries. PM&R KnowledgeNow

7) Bladder training & pelvic-floor therapy.
Goal: fewer urgency/leak episodes. Mechanism: timed voiding, fluid timing, pelvic-floor relaxation/strengthening, and urge-suppression strategies retrain reflex pathways and improve continence; complements medications when needed. PM&R KnowledgeNow

8) Bowel routine & fiber/fluid plan.
Goal: prevent constipation (a common spasticity trigger). Mechanism: scheduled toileting, adequate fluid, and gradual fiber increase support colonic motility; suppositories or osmotic agents can be added if needed. PM&R KnowledgeNow

9) Fall-prevention & home safety.
Goal: fewer injuries. Mechanism: remove trip hazards, add railings, use non-slip mats, improve lighting, and practice safe turning/transfer techniques to counter scissoring gait and spastic catches. PM&R KnowledgeNow

10) Pressure-relief education.
Goal: protect skin in people with low mobility. Mechanism: scheduled weight shifts, cushions, and posture checks reduce shear/pressure on bony areas. PM&R KnowledgeNow

11) Speech-language & swallowing support (if needed).
Goal: safer communication and eating where bulbar issues exist. Mechanism: compensatory strategies and diet texture adjustments reduce aspiration risk and conserve energy. PMC

12) Vision & oculomotor therapy for nystagmus.
Goal: steadier gaze, better reading. Mechanism: optical aids, head-posture strategies, and environmental adjustments ease symptoms during near tasks. rarediseases.info.nih.gov

13) Pain self-management (heat, stretching, pacing).
Goal: ease muscle pain from over-activity. Mechanism: heat relaxes muscles; gentle stretch resets muscle spindle sensitivity; activity pacing avoids spasm triggers. PMC

14) Aerobic conditioning (low-impact).
Goal: endurance without spasticity spikes. Mechanism: recumbent cycling or water-based exercise raises aerobic capacity and supports neuroplasticity while minimizing velocity-dependent tone increases. PMC

15) Hydrotherapy.
Goal: easier movement and stretching. Mechanism: buoyancy unloads joints; warm water reduces spasticity allowing longer ROM work and gait practice. PMC

16) Night-time positioning systems.
Goal: maintain hip/ankle alignment. Mechanism: pillows/wedges prevent scissoring and internal rotation that otherwise reinforce contracture overnight. PM&R KnowledgeNow

17) School & workplace accommodations.
Goal: sustained participation. Mechanism: extra time for transitions, accessible routes, and adaptive tech reduce fatigue/falls and preserve productivity. PM&R KnowledgeNow

18) Psychology & coping skills.
Goal: reduce stress-tone cycle. Mechanism: CBT, mindfulness, and problem-solving training lower anxiety and improve adherence to daily therapy. PMC

19) Specialist multidisciplinary follow-up.
Goal: coordinated, stage-appropriate care. Mechanism: regular review by neuro/rehab/OT/PT/urology/ophthalmology adjusts plans as needs evolve (guideline consensus). ScienceDirect

20) Patient/community organizations.
Goal: information & peer support. Mechanism: education, registries, and expert lists speed access to knowledgeable clinicians and trials. rarediseases.info.nih.gov

---

Drug treatments

Important: These medicines treat symptoms common in HSP (spasticity, bladder urgency, neuropathic pain). They are not disease-modifying for SPG60. Doses are typical adult starting ranges; clinicians individualize based on age, kidney/liver function, and other meds.

1) Oral baclofen.
Class: GABA-B agonist antispastic. Dose/time: start 5–10 mg at night, then 5–10 mg three times daily; titrate to effect while watching sedation. Purpose: reduce stretch-reflex hyper-excitability and clonus. Mechanism: presynaptic inhibition in spinal cord dampens excitatory neurotransmitter release. Side effects: sleepiness, weakness; avoid abrupt stop (withdrawal). FDA label supports spasticity indication. FDA Access Data+1

2) Tizanidine.
Class: central α2-agonist antispastic. Dose/time: 2 mg up to three times daily, increase cautiously; limit to needed times because effect is short. Purpose: drop muscle tone for key activities. Side effects: sleepiness, low BP, dry mouth; watch liver enzymes and drug interactions. FDA-labeled for spasticity. FDA Access Data+1

3) Dantrolene.
Class: peripheral muscle relaxant. Dose: 25 mg daily, gradually up to 100 mg four times daily if tolerated. Purpose: reduce stiff, cramping muscles by lowering calcium release from the sarcoplasmic reticulum. Caution: hepatotoxicity risk; monitor LFTs. FDA label includes spasticity with boxed warnings. FDA Access Data

4) Intrathecal baclofen (implantable pump).
Class: spinal GABA-B agonist delivered to CSF. Dose: screening bolus then continuous pump titration. Purpose: strong tone reduction with fewer whole-body side effects when oral therapy fails. Risks: withdrawal if delivery stops; infection; catheter issues. FDA-labeled for severe spasticity. FDA Access Data+1

5) OnabotulinumtoxinA (Botox) for focal spasticity.
Class: neuromuscular blocker. Dose: muscle-specific units every ~12 weeks. Purpose: relax overactive calf/adductors to improve brace-fit and gait. Side effects: weakness at injection site; rare systemic spread warning. FDA labeling covers limb spasticity and neurogenic bladder indications. FDA Access Data+1

6) Oxybutynin (for bladder urgency).
Class: antimuscarinic. Dose: IR 2.5–5 mg two-three times daily or ER 5–10 mg daily. Purpose: calm detrusor overactivity to reduce frequency/urge leakage. Effects: dry mouth, constipation, blurry vision. FDA-labeled for overactive bladder symptoms. FDA Access Data+1

7) Tolterodine.
Class: antimuscarinic. Dose: IR 1–2 mg twice daily or LA 2–4 mg daily; adjust for hepatic/renal disease. Purpose/mechanism similar to oxybutynin with often better tolerability. Watch QT interactions at high exposure. FDA-labeled. FDA Access Data+2FDA Access Data+2

8) Mirabegron.
Class: β3-agonist for overactive bladder. Dose: 25–50 mg once daily; monitor BP and CYP2D6 interactions. Purpose: relax detrusor during filling without anticholinergic side effects. FDA-labeled for OAB; useful when antimuscarinics not tolerated. FDA Access Data+1

9) Gabapentin (neuropathic pain/paresthesias).
Class: α2δ calcium-channel modulator. Dose: 100–300 mg at night → gradually 300 mg three times daily; adjust for renal function. Purpose: ease burning/tingling pain that sometimes complicates HSP. Side effects: dizziness, somnolence. FDA-labeled for neuropathic pain and seizures. FDA Access Data

10) Pregabalin.
Class: α2δ modulator. Dose: 50–75 mg twice daily up to 300–450 mg/day; taper to stop. Purpose: alternative to gabapentin for neuropathic pain and sleep. Side effects: edema, weight gain; suicidality warning as for AEDs. FDA-labeled. FDA Access Data+1

11) Diazepam (limited, short-term).
Class: benzodiazepine muscle relaxant. Dose: 2–5 mg at bedtime or twice daily if needed. Purpose: brief relief of spasms or nocturnal cramps when other drugs insufficient. Risks: sedation, dependence; reserve for short courses. FDA labeling includes muscle spasm; use cautiously. Medscape

12) Botulinum toxin for neurogenic bladder (select cases).
Class: intradetrusor onabotulinumtoxinA. Dose: cystoscopic injections per label. Purpose: reduce refractory urgency/incontinence in neurogenic detrusor overactivity when pills fail. Risks: urinary retention requiring intermittent catheterization. FDA-labeled. FDA Access Data

13) Topical antispasmodic heat rubs (adjunct only).
Purpose: temporary comfort; minimal systemic effects. Mechanism: counter-irritation and local blood-flow increase reduce perceived stiffness. Use as supplement, not primary therapy. PMC

14) Magnesium (for nocturnal cramps; medical supervision).
Purpose: may ease calf cramps in some; avoid high doses in renal disease. Mechanism: NMDA and calcium handling modulation. Evidence is mixed; discuss with clinician. PMC

15) Baclofen oral solution/granules formulations.
Same mechanism as #1; flexible dosing for children or those with swallowing issues. Withdrawal warnings are the same. FDA labels exist for multiple baclofen formulations. FDA Access Data+1

16) Detrusor relaxants combo (mirabegron + low-dose antimuscarinic).
Purpose: add benefit when single-agent therapy inadequate. Mechanism: β3 plus M-receptor blockade improves storage with fewer anticholinergic burdens than high-dose monotherapy; watch BP and interactions. FDA Access Data

17) Pain ladder (acetaminophen/NSAIDs) as needed.
Purpose: musculoskeletal pain relief from overuse/contracture. Use lowest effective NSAID dose; protect GI/renal risk. Not HSP-specific but standard. Medscape

18) Sleep aids (non-drug first; short-term meds only if needed).
Purpose: improve sleep disrupted by spasms; better sleep reduces daytime tone. Prioritize sleep hygiene; if medication needed, use with caution. PMC

19) Bowel meds (osmotic laxatives) for constipation.
Purpose: keep regular to prevent spasticity flares. Polyethylene glycol is common; titrate to soft daily stool. PM&R KnowledgeNow

20) Vitamin D/calcium when mobility is low (fracture prevention).
Purpose: support bone health alongside weight-bearing, per general neurodisability care. Monitor levels and interactions. PM&R KnowledgeNow

---

Dietary molecular supplements

1) Omega-3 fatty acids (fish oil).
Why: may help chronic neuro-inflammation and general cardiovascular health; small analgesic effect for neuropathic pain in some. Mechanism: EPA/DHA modify inflammatory lipid mediators and membrane fluidity. Use: ~1 g/day combined EPA+DHA with meals; watch antiplatelet interactions. Evidence supportive in neuropathic pain and general neuro health, but not SPG60-specific. Frontiers

2) Coenzyme Q10.
Why: mitochondrial support in disorders with axonal stress. Mechanism: electron transport cofactor and antioxidant. Use: 100–200 mg/day; may aid fatigue. Evidence mixed; safe at typical doses. Frontiers

3) Alpha-lipoic acid.
Why: neuropathic pain adjunct. Mechanism: antioxidant; improves glucose-induced oxidative stress in nerves. Use: 300–600 mg/day; can lower blood sugar—monitor. Frontiers

4) Vitamin D3.
Why: bone health and muscle function if low. Mechanism: calcium-phosphate regulation and muscle gene expression. Use: dose to target serum 25-OH D per clinician. PM&R KnowledgeNow

5) Magnesium glycinate/citrate.
Why: nocturnal cramps/constipation help. Mechanism: NMDA modulation and osmotic effect (citrate). Use: 200–400 mg elemental Mg/day; avoid in renal failure. PMC

6) Creatine monohydrate.
Why: small strength/endurance gains in some neuromuscular disorders. Mechanism: phosphocreatine energy buffer. Use: 3–5 g/day; hydrate. Frontiers

7) Curcumin (with piperine or a bioavailable form).
Why: anti-inflammatory adjunct for aches. Mechanism: NF-κB pathway modulation. Use: 500–1000 mg/day curcuminoids; check drug interactions. Frontiers

8) B-complex (esp. B12 if low).
Why: supports peripheral nerve health when deficient. Mechanism: myelin and axonal metabolism. Dose: per lab levels; avoid mega-doses without indication. Frontiers

9) L-carnitine.
Why: may help fatigue; mitochondrial shuttling of fatty acids. Use: 500–1000 mg twice daily; GI upset possible. Evidence limited. Frontiers

10) Probiotics/fiber supplement.
Why: bowel regularity and comfort. Mechanism: microbiome and stool bulk effects. Use: titrate fiber slowly with fluids. PM&R KnowledgeNow

---

Immunity booster / regenerative / stem-cell–type” medicines

1) Vaccinations (core & flu).
Not a “drug to boost immunity,” but staying up-to-date lowers infection-triggered setbacks that increase spasticity. Mechanism: adaptive immune priming. Use: follow national schedules. ScienceDirect

2) Vitamin D repletion (if deficient).
Supports innate/adaptive immunity and bone/muscle health; treat deficiency per labs. PM&R KnowledgeNow

3) No approved stem-cell drug for SPG60.
Current literature shows experimental work in HSP broadly; no licensed regenerative or gene therapy exists for WDR48-related HSP as of Oct 13, 2025. Mechanism-based therapies are under study. Decisions should occur within regulated clinical trials only. Frontiers+1

4) Antioxidant adjuncts (CoQ10/ALA).
As above, they target oxidative stress but are supportive, not curative; monitor interactions. Frontiers

5) Physical training as neuro-restorative stimulus.
Repeated, task-specific practice drives spinal and cortical plasticity; this is the most evidence-aligned “regenerative” input available now. PMC

6) Clinical-trial enrollment when available.
Access to emerging strategies (e.g., pathway-targeted or neurorehab tech). Check registries and HSP foundations. rarediseases.info.nih.gov

---

Procedures / surgeries

1) Intrathecal baclofen pump implantation.
Why: severe diffuse spasticity not controlled with pills or focal injections. Procedure: test dose via lumbar puncture; if effective, pump/catheter placed under skin to infuse baclofen into CSF. Benefits: strong tone relief with fewer systemic effects; risks: withdrawal if pump/catheter fails, infection. FDA Access Data

2) Botulinum toxin chemodenervation.
Why: focal problematic muscles (e.g., calf, adductors) causing toe-walk, scissoring, or brace issues. Procedure: ultrasound/EMG-guided intramuscular injections every ~3 months. FDA Access Data

3) Orthopedic tendon-lengthening (selected cases).
Why: fixed contracture that blocks bracing or hygiene. Procedure: lengthen Achilles/hamstrings or adductors; intensive post-op therapy and bracing follow. PM&R KnowledgeNow

4) Selective dorsal rhizotomy (very rare in HSP).
Why: refractory spasticity with careful selection; more common in CP than HSP. Mechanism: cuts dorsal rootlets to reduce reflex arc excitability; risk of sensory changes/weakness. Considered case-by-case. PM&R KnowledgeNow

5) Urologic procedures for refractory neurogenic bladder.
Why: repeated infections/incontinence despite meds/injections. Options: Botox to detrusor, augmentation cystoplasty in extreme cases. FDA Access Data

---

Preventions

1. Daily stretch routine (hips, knees, ankles) to prevent contractures. PMC

2. Fall-proof your home (rails, remove clutter, proper footwear). PM&R KnowledgeNow

3. Keep bowels regular; constipation spikes spasticity. PM&R KnowledgeNow

4. Hydration and bladder schedule to limit urgency and UTIs. PM&R KnowledgeNow

5. Skin checks and pressure relief if sitting long periods. PM&R KnowledgeNow

6. Vaccinations and prompt infection care to avoid deconditioning. ScienceDirect

7. Maintain gentle aerobic fitness to reduce fatigue and tone. PMC

8. Review meds regularly to avoid polypharmacy and interactions. ScienceDirect

9. Regular eye and vision support if nystagmus affects reading. rarediseases.info.nih.gov

10. Schedule multidisciplinary reviews to update braces, equipment, goals. ScienceDirect

---

When to see doctors urgently

See a clinician promptly if you notice: sudden worsening stiffness or new weakness; loss of walking ability over days to weeks; severe back pain with fever; bladder retention or very frequent UTIs; new swallowing problems; repeated falls; new visual symptoms or rapid nystagmus change; pump alarms, redness, or withdrawal symptoms if you have an intrathecal baclofen pump (high fever, severe spasms, confusion); or serious side effects from medications (e.g., extreme sleepiness, fainting, yellow eyes/skin with dantrolene). These red flags often indicate treatable complications or medication issues that should not wait. FDA Access Data+1

---

What to eat and what to avoid

1. Eat: high-fiber foods (oats, lentils, vegetables) to keep bowels regular; Avoid: big low-fiber meals that worsen constipation. PM&R KnowledgeNow

2. Eat: lean proteins for muscle repair; Avoid: skipping protein after therapy days. PMC

3. Drink: steady water intake; Avoid: late-evening excess fluids if urgency at night is a problem. PM&R KnowledgeNow

4. Include: magnesium-rich foods (nuts, legumes) for cramps; Avoid: over-supplementing without doctor advice. PMC

5. Use: omega-3 sources (fish, flax) for general anti-inflammatory support; Avoid: highly processed, high-salt foods that worsen blood pressure/edema. Frontiers

6. Consider: vitamin D/calcium sources for bone health if mobility limited; Avoid: excess caffeine if it worsens urgency. PM&R KnowledgeNow

7. Time: smaller meals before therapy to reduce fatigue; Avoid: heavy meals that increase tone and make training hard. PMC

8. If weight trending up: choose lower-energy-density foods; Avoid: sugary drinks that add calories but no nutrients. PMC

9. For reflux from bend/tone: take smaller, upright meals; Avoid: eating right before lying down. PMC

10. If constipation persists: add psyllium gradually and keep fluids up; Avoid: sudden large fiber increases without water. PM&R KnowledgeNow

---

Frequently asked questions

1) Is there a cure for SPG60 today?
No disease-modifying drug exists yet; treatment is symptomatic with rehab, spasticity control, and bladder/bowel/vision support. Clinical trials may open in the future. PMC+1

2) Which gene is involved?
SPG60 is linked to WDR48 (UAF1) on chromosome 3; it partners with deubiquitinating enzymes. GeneCards+1

3) How is the diagnosis made?
Through clinical exam plus genetic testing, usually with a multigene HSP panel or exome. rarediseases.info.nih.gov

4) Will physiotherapy really help long-term?
Yes—regular stretching, strengthening, and gait practice slow secondary problems and improve function even without a cure. PMC

5) What’s the first-line drug for spasticity?
Oral baclofen or tizanidine are typical starters; choice depends on side-effect profile and daily routine. FDA Access Data+1

6) What if pills don’t work or cause side effects?
Options include targeted botulinum toxin for focal muscles or intrathecal baclofen for severe diffuse tone. FDA Access Data+1

7) Are anticholinergics the only bladder option?
No. Mirabegron (β3-agonist) or Botox to the bladder can help when antimuscarinics fail or cause side effects. FDA Access Data+1

8) Can exercise worsen spasticity?
High-velocity, fatiguing bursts can spike tone temporarily, but well-paced, low-impact aerobic and strengthening work is beneficial. PMC

9) Is surgery common?
Not routine. It’s considered for fixed contractures (orthopedics) or for pump placement in severe spasticity. FDA Access Data

10) What about stem cells?
No approved stem-cell therapy for SPG60; consider clinical trials only within regulated settings. PMC

11) Do supplements replace medicines?
No. Supplements are supportive at best; they can interact with drugs. Discuss each with your clinician. Frontiers

12) Why do infections make stiffness worse?
Fever, dehydration, and inflammation lower thresholds for reflexes and can trigger spasms; prevention and early treatment help. ScienceDirect

13) How often should braces and devices be reviewed?
At least yearly or sooner after growth/functional change; poor fit increases falls and skin problems. ScienceDirect

14) Can vision therapy help nystagmus?
Supportive strategies and optical aids can improve comfort for reading/near work even if nystagmus persists. rarediseases.info.nih.gov

15) Where can families find expert centers or communities?
HSP foundations and rare-disease networks list experts, centers, and registries to speed access to specialized care. rarediseases.info.nih.gov

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.